From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Nigel Somerville’s 2015 share tips of the year – No 1: Scancell

By Nigel Somerville | Saturday 27 December 2014


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Scancell (SCLP) is a biotech stock I’ve been keen on for some four or five years. The statistics on getting new treatments through clinical trials and regulatory approvals are terrible, so we are certainly at the high-risk end of the spectrum, but I believe the risk/reward is favourable and I like the company, management, the way it behaves (important!) and the products currently being developed. Here is why.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

PICH

Pitch Pit – this stinks

 

GEX

Georgina Energy: Lyin’ Yet again

Time left: 04:37:12